Controversias en el Cribado de Cáncer de Próstata: ¿es útil el Antígeno Prostático Específico?
DOI:
https://doi.org/10.19230/jonnpr.3204Keywords:
Prostate Cancer, Prostate Specific Antigen (PSA), ScreeningAbstract
Prostate cancer is one of the most important cancers in recent years, due to its high incidence and prevalence in the world population. The use of prostate cancer screening using Prostate Specific Antigen (PSA) has contributed to increasing the early diagnosis of this cancer, but also the overdiagnosis and over- treatment of this cancer. Numerous studies have attempted to find statistically significant evidence to demonstrate the decrease in mortality of patients performing screening. Two large studies stand out in this field and are the American PLCO study, which has not found a decrease in mortality and the European ERSPC study that has found it.
The conditions of use of PSA in the population are not entirely clear, although as it has been studied, it is necessary to use screening for at least 10 years to demonstrate a decrease in prostate cancer mortality. That is why, there is a clear contraindication and it is its use in patients over 70 years because they do not have enough life expectancy for the screening to show any benefit. In the case of an asymptomatic population, the patient must decide if they want to be screened according to the benefits and risks they assume.
This work aims to carry out an expanded review of the evidence of prostate cancer screening using PSA and see under what conditions it would be indicated to undergo such screening.
Downloads
References
López PJT, Albero JS, Rodríguez-Montes JA. Primary and Secondary Prevention of Colorectal Cancer. Clin Med Insights Gastroenterol. 1 de enero de 2014;7:CGast.S14039.
Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 1 de noviembre de 2018;103:356-87.
Galceran J, Ameijide A, Carulla M, Mateos A, Quirós JR, Rojas D, et al. Cancer incidence in Spain, 2015. Clin Transl Oncol. 1 de julio de 2017;19(7):799-825.
Marzo-Castillejo M, Vela-Vallespín C, Bellas-Beceiro B, Bartolomé-Moreno C, Melús-Palazón E, Vilarrubí-Estrella M, et al. Recomendaciones de prevención del cáncer. Actualización PAPPS 2018. Aten Primaria. 1 de mayo de 2018;50:41-65.
REDECAN - Estimaciones de la incidencia del cáncer en España, 2019 [Internet]. [citado 8 de marzo de 2019]. Disponible en: http://redecan.org/es/page.cfm?id=210&title=estimaciones-de-la-incidencia-del-canceren-espana,-2019
DENNIS K. Harrison. Principios de medicina interna - 19a Edición, volúmenes 1-2. Edición: 19. Aravaca, Madrid: LUIV4; 2016. 3235 p.
Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. agosto de 1993;150(2 Pt 1):379-85.
Patel AR, Klein EA. Risk factors for prostate cancer. Nat Rev Urol. febrero de 2009;6(2):87-95.
Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiol Camb Mass. enero de 2002;13(1):72-9.
Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology. julio de 2002;60(1):78-83.
Giménez N, Filella X, Gavagnach M, Allué JA, Pedrazas D, Ferrer F. Cribado del cáncer de próstata mediante antígeno prostático específico: perspectiva del médico en atención primaria y en el laboratorio clínico. Med Fam SEMERGEN. 1 de septiembre de 2018;44(6):409-19.
Jalón Monzón A, Escaf Barmadah S, Viña Alonso LM, Jalón Monzón M. Aspectos actuales sobre el cribado en el cáncer de próstata. SEMERGEN - Med Fam. 1 de julio de 2017;43(5):387-93.
Barry MJ. Prostate-Specific–Antigen Testing for Early Diagnosis of Prostate Cancer. N Engl J Med. 3 de mayo de 2001;344(18):1373-7.
Vivo Ocaña A. Diseño y evaluación de un modelo predictivo para el diagnóstico del cáncer de próstata en Atención Primaria. 2012 [citado 18 de febrero de 2019]; Disponible en: https://repositorio.uam.es/handle/10486/11318
Martínez Jabaloyas JM, García Morata F, Villamón Fort R, Pastor Hernández F, Gil Salom M, García Sisamón F. Valor de la densidad del antígeno prostático específico y de la densidad del antígeno prostático específico de la zona transicional en el diagnóstico del cáncer de próstata. Actas Urol Esp. junio de 2003;27(6):442-9.
Morote J, Maldonado X, Morales-Bárrera R. Cáncer de próstata. Med Clínica. 5 de febrero de 2016;146(3):121- 7.
Brenes Bermúdez FJ, Alcántara Montero A. ¿Detección precoz o cribado en la prevención del cáncer de próstata? SEMERGEN - Med Fam. 1 de marzo de 2017;43(2):100-8.
Hayes RB, Ziegler RG, Gridley G, Swanson C, Greenberg RS, Swanson GM, et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. enero de 1999;8(1):25-34.
Zu K, Giovannucci E. Smoking and aggressive prostate cancer: a review of the epidemiologic evidence. Cancer Causes Control. 1 de diciembre de 2009;20(10):1799-810.
Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers The Selenium and Vitamin E Cancer Prevention Trial ( SELECT). Jama-J Am Med Assoc. 7 de enero de 2009;301(1):39-51.
Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The Influence of Finasteride on the Development of Prostate Cancer. N Engl J Med. 17 de julio de 2003;349(3):215-24.
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of Dutasteride on the Risk of Prostate Cancer. N Engl J Med. 1 de abril de 2010;362(13):1192-202.
Pinto Á, Segura PP. Primary prevention and early diagnosis of prostate cancer: recommendations from the prevention and early diagnosis working group of the Spanish Society of Medical Oncology (seom). Eur J Cancer Prev. 1 de marzo de 2016;25(2):137-41.
Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Prostate-Cancer Mortality at 11 Years of Follow-up [Internet]. http://dx.doi.org/10.1056/NEJMoa1113135. 2012 [citado 1 de octubre de 2018]. Disponible en: https://www.nejm.org/doi/10.1056/NEJMoa1113135?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dwww.ncbi.nlm.nih.gov
Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Zappa M, Nelen V, et al. The European Randomized Study of Screening for Prostate Cancer – Prostate Cancer Mortality at 13 Years of Follow-up. Lancet. 6 de diciembre de 2014;384(9959):2027-35.
Buzzoni C, Auvinen A, Roobol MJ, Carlsson S, Moss SM, Puliti D, et al. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 1 de noviembre de 2015;68(5):885-90.
Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 15 de febrero de 2017;123(4):592-9.
Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. agosto de 2010;11(8):725-32.
Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 31 de enero de 2013;(1):CD004720.
Catalona W, Richie J, Ahmann F, Hudson M, Scardino P, Flanigan R, et al. Comparison of Digital Rectal Examination and Serum Prostate-Specific Antigen in the Early Detection of Prostate-Cancer - Results of a Multicenter Clinical-Trial of 6,630 Men. J Urol. mayo de 1994;151(5):1283-90.
Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 17 de julio de 2012;157(2):120-34.
Brenes Bermúdez FJ. Uso del antígeno prostático específico en atención primaria. SEMERGEN - Med Fam. 1 de abril de 2017;43(3):173-4.
Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials. agosto de 2010;7(4):303-11.
Shoag JE, Mittal S, Hu JC. Reevaluating PSA Testing Rates in the PLCO Trial. N Engl J Med. 5 de mayo de 2016;374(18):1795-6.
Schroder FH, Hugosson J, Roobol MJ, Tammela TLJ, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 6 de diciembre de 2014;384(9959):2027-35.
Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 8 de mayo de 2018;319(18):1901-13.
Bibbins-Domingo K, Grossman DC, Curry SJ. The US Preventive Services Task Force 2017 Draft Recommendation Statement on Screening for Prostate Cancer: An Invitation to Review and Comment. JAMA. 16 de mayo de 2017;317(19):1949-50.
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAUESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. abril de 2017;71(4):618-29.
Cepeda Piorno J, Rivas del Fresno M, Fuente Martín E, González García E, Muruamendiaraz Fernández V, Fernández Rodríguez E. [Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)]. Arch Esp Urol. junio de 2005;58(5):403-11.
Panach-Navarrete J, Gironés-Montagud A, Sánchez-Cano E, Doménech-Pérez C, Martínez-Jabaloyas JM. Uso del antígeno prostático específico en atención primaria (PSA). SEMERGEN - Med Fam. 1 de abril de 2017;43(3):189-95.
Sopeña-Sutil R, Tejido-Sánchez A, Galván-Ortiz de Urbina M, Guerrero-Ramos F, García-Álvarez G, Passas- Martínez JB. Evolución de las derivaciones de atención primaria a urología. Impacto de un protocolo en enfermedad prostática y de formación continuada. Actas Urol Esp. 1 de junio de 2015;39(5):296-302.
Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PFA, et al. Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy. Eur Urol. noviembre de 2008;54(5):1081-8.
Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I, Henderson RJ, et al. PCA3 Molecular Urine Test as a Predictor of Repeat Prostate Biopsy Outcome in Men with Previous Negative Biopsies: A Prospective Multicenter Clinical Study. J Urol. julio de 2013;190(1):64-9.
Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, et al. Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program. J Urol. febrero de 2010;183(2):534-8.
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 28 de octubre de 2005;310(5748):644-8.
Tomlins SA, Aubin SMJ, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, et al. Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA. Sci Transl Med. 3 de agosto de 2011;3(94):94ra72.
Dijkstra S, Govers TM, Hendriks RJ, Schalken JA, Van Criekinge W, Van Neste L, et al. Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model. Bju Int. noviembre de 2017;120(5):659-65.
Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, et al. A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range. J Urol. mayo de 2011;185(5):1650-5.
Lazzeri M, Briganti A, Scattoni V, Lughezzani G, Larcher A, Gadda GM, et al. Serum Index Test %[-2]proPSA and Prostate Health Index are More Accurate than Prostate Specific Antigen and %fPSA in Predicting a Positive Repeat Prostate Biopsy. J Urol. octubre de 2012;188(4):1137-43.
Stattin P, Vickers AJ, Sjoberg DD, Johansson R, Granfors T, Johansson M, et al. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostatespecific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study. Eur Urol. agosto de 2015;68(2):207-13.
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
